The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Vogel, Ulrich ^a   Stefanelli, Paola ^b   Vazquez, Julio ^c   Taha, Muhamed Kheir ^d   Claus, Heike ^a   Donnelly, John ^e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUT PASTEUR   (France)

^e Research Serology Novartis Vaccines and Diagnostics   (United States)

Author keywords

ELISA; Neisseria meningitidis; Public health; Reference laboratory; Serum bactericidal assay; Vaccine

Indexed keywords

4CMENB; BACTERIAL ANTIGEN; FHBP ANTIGEN; MENINGOCOCCUS B VACCINE; MENINGOCOCCUS VACCINE; NADA ANTIGEN; NHBA ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIOLOGICAL TECHNIQUES; CROSS REACTIONS; HUMANS; IMMUNOLOGIC TECHNIQUES; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84861139717     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.061     Document Type: Article

References (33)

1. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362(April (16)):1511-1520.
2. Achtman M., Wagner M. Microbial diversity and the genetic nature of microbial species. Nat Rev Microbiol 2008, 6(June (6)):431-440.
3. Claus H., Borrow R., Achtman M., Morelli G., Kantelberg C., Longworth E., et al. Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol 2004, 51(January (1)):227-239.
4. Vogel U., Hammerschmidt S., Frosch M. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitidis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med Microbiol Immunol 1996, 185(September (2)):81-87.
5. Vogel U., Claus H. Vaccine development against Neisseria meningitidis. Microb Biotechnol 2010, 4(May (1)):20-31.
6. Jolley K.A., Brehony C., Maiden M.C. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007, 31(January (1)):89-96.
7. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23(March (17-18)):2222-2227.
8. Holst J., Feiring B., Naess L.M., Norheim G., Kristiansen P., Hoiby E.A., et al. The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23(March (17-18)):2202-2205.
9. Caron F., du Chatelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11(June (6)):455-463.
10. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(July (29)):10834-10839.
11. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(August (37)):6086-6093.
12. Brunelli B., del Tordello E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine 2011, 29:1072-1081.
13. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107(November (45)):19490-19495.
14. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(March (17-18)):2191-2196.
15. van der Ende A., Hopman C.T., Keijzers W.C., Spanjaard L., Lodder E.B., van Keulen P.H., et al. Outbreak of meningococcal disease caused by PorA-deficient meningococci. J Infect Dis 2003, 187(March (5)):869-871.
16. Schrauder A., Claus H., Elias J., Vogel U., Haas W., Hellenbrand W. Capture-recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003. Epidemiol Infect 2006, 135(August (4)):657-664.
17. Nadel S., Kroll J.S. Diagnosis and management of meningococcal disease: the need for centralized care. FEMS Microbiol Rev 2007, 31(January (1)):71-83.
18. Birtles A., Hardy K., Gray S.J., Handford S., Kaczmarski E.B., Edwards-Jones V., et al. Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters. J Clin Microbiol 2005, 43(December (12)):6007-6014.
19. Vazquez J.A., Arreaza L., Block C., Ehrhard I., Gray S.J., Heuberger S., et al. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 2003, 47(November (11)):3430-3434.
20. Taha M.K., Alonso J.M., Cafferkey M., Caugant D.A., Clarke S.C., Diggle M.A., et al. Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol 2005, 43(January (1)):144-149.
21. Vogel U. Molecular epidemiology of meningococci: application of DNA sequence typing. Int J Med Microbiol 2010, 300(May (7)):415-420.
22. Jolley K.A., Maiden M.C. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 2010, 11:595.
23. Jolley K.A., Maiden M.C. AgdbNet - antigen sequence database software for bacterial typing. BMC Bioinformatics 2006, 7:314.
24. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197(March (5)):737-743.
25. Caugant D.A., Tzanakaki G., Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007, 31(January (1)):52-63.
26. Claus H., Maiden M.C., Wilson D.J., McCarthy N.D., Jolley K.A., Urwin R., et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005, 191(April (8)):1263-1271.
27. Schielke S., Huebner C., Spatz C., Nagele V., Ackermann N., Frosch M., et al. Expression of the meningococcal adhesin NadA is controlled by a transcriptional regulator of the MarR family. Mol Microbiol 2009, 72(May (4)):1054-1067.
28. Metruccio M.M., Pigozzi E., Roncarati D., Berlanda S.F., Norais N., Hill S.A., et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 2009, 5(December (12)):e1000710.
29. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009, 27(March (10)):1579-1584.
30. Taha M.K., Vazquez J.A., Hong E., Bennett D.E., Bertrand S., Bukovski S., et al. Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrob Agents Chemother 2007, 51(August (8)):2784-2792.
31. Elias J., Harmsen D., Claus H., Hellenbrand W., Frosch M., Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 2006, 12(November (11)):1689-1695.
32. Brehony C., Jolley K.A., Maiden M.C. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007, 31(January (1)):15-26.
33. Claus H., Jördens M.S., Kriz P., Musilek M., Jarva H., Pawlik M.-C., et al. Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine. Vaccine 2012, 30(2):155-160.